CNTB vs. INMB, MDWD, CTNM, FULC, MOLN, CGEN, PLX, PRQR, INBX, and CYBN
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include INmune Bio (INMB), MediWound (MDWD), Contineum Therapeutics (CTNM), Fulcrum Therapeutics (FULC), Molecular Partners (MOLN), Compugen (CGEN), Protalix BioTherapeutics (PLX), ProQR Therapeutics (PRQR), Inhibrx (INBX), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry.
Connect Biopharma vs.
INmune Bio (NASDAQ:INMB) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.
INmune Bio has higher earnings, but lower revenue than Connect Biopharma.
INmune Bio presently has a consensus price target of $22.80, indicating a potential upside of 165.42%. Connect Biopharma has a consensus price target of $8.00, indicating a potential upside of 819.43%. Given Connect Biopharma's higher possible upside, analysts clearly believe Connect Biopharma is more favorable than INmune Bio.
12.7% of INmune Bio shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, INmune Bio had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for INmune Bio and 0 mentions for Connect Biopharma. INmune Bio's average media sentiment score of 1.00 beat Connect Biopharma's score of 0.00 indicating that INmune Bio is being referred to more favorably in the media.
INmune Bio has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.
Connect Biopharma's return on equity of 0.00% beat INmune Bio's return on equity.
INmune Bio received 126 more outperform votes than Connect Biopharma when rated by MarketBeat users. Likewise, 76.60% of users gave INmune Bio an outperform vote while only 72.00% of users gave Connect Biopharma an outperform vote.
Summary
INmune Bio beats Connect Biopharma on 11 of the 16 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CNTB) was last updated on 2/22/2025 by MarketBeat.com Staff
